anti-PD-(L)1 immunotherapy

Combinatorial Immunotherapy Strategy: CatalYm Advances Visugromab in Advanced Liver Cancer

Post author:Bree Clare
Post published:April 15, 2026
Post category:Hepatocellular Carcinoma

CatalYm has initiated patient enrollment in the GDFATHER-HCC-01 trial, a Phase 2b study investigating visugromab as part of a combinatorial treatment strategy for patients with unresectable or metastatic hepatocellular carcinoma…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More